The future of the global internal hemorrhagic fever inactivated vaccine market looks promising with opportunities in the hospitals, clinics markets.
- Within the type category, yellow fever vaccine is expected to witness higher growth over the forecast period due to widespread use in endemic regions and travel health requirement.
- Within the application category, clinics is expected to witness the higher growth due to most vaccinations are administered at travel clinics or primary healthcare.
- In terms of regions, ROW is expected to witness the highest growth over the forecast period due to recurrent outbreaks of Ebola and other hemorrhagic fever diseases.
Emerging Trends in Internal Hemorrhagic Fever Inactivated Vaccine Market
During the period of 2025-2027, the internal hemorrhagic fever inactivated vaccine market will move from emergency stockpiling to sustained preparedness. This will be marked by regional manufacturing by governments, regulators demanding increased evidentiary standards, and developers focusing on the safety, speed, and field deployment of vaccine platforms. Lucintel should broaden the scope of its market perspective to include purchasing structures rather than just pipeline science.- Sustainability: Running counter to 2025 public tenders, which incorporate lifecycle criteria, developers are building pilot projects with reduced single use and waste as well as reduced energy intensity. WHO’s 2024 guide prefigures systems designed for repeated deployment over campaign specific systems and will drive procurement outcomes.
- Regional Supply Chain Diversification: From 2025, governments in Africa, the Middle East, and Asia will request domestic fill-finish capacity, technology transfer, and dual sourcing as opposed to over-reliance on a single offshore supplier. Having two or more sources will be the new benchmark for operational resilience. Over the next 3-5 years, it is expected that procurement will resources will favor geographically dispersed manufacturing.
- Digital Manufacturing: Vaccine facilities that support hemorrhagic fever programs are beginning to incorporate automated processes, quality systems, and process analytics. By 2025, the focus of validation activities will be the ability to make decisions to release product in a matter of days rather than weeks. This will contribute to improving the traceability and speed of scale up while increasing confidence of regulators toward smaller regional vaccine production plants.
- Functional Products: Developers are looking at thermal stabilities, simplified dosing, and innovations in packaging formats that are appropriate for remote clinics. Within the next few years, there are programs looking to create products with dose formulations where cold chain is not a constant consideration. Even a product that only requires 2°C-8°C thermos stability is very challenging to deploy during an outbreak. Therefore, how easy it is to use a product will determine how quickly it is adopted and how long it will take for a vaccine to gain immunity over the disease.
- Regulatory Harmonization: Within the next few years, the various components of an “emergency use” pathway (i.e. shared clinical protocols, reliance reviews) and single country studies, will become increasingly important. In the case that single country clinical studies will take a long time, there is a great possibility for “common dossiers” to be used, thereby eliminating duplication of work in different regions. This will also potentially increase the market that can be served, but sponsor companies must still collect quality safety data on their inactivated products.
Recent Developments in the Internal Hemorrhagic Fever Inactivated Vaccine Market
The internal hemorrhagic fever inactivated vaccine market is becoming more focused on planned procurement than on emergency preparedness. Between 2025 and 2027, activities will consist of outbreak trials, platform validation, manufacturing readiness, and public funding. Lucintel anticipates bursts of demand. Governments will create stockpiles in anticipation of outbreaks, rather than after.- Outbreak Trials Sanctioned By Government: The first Marburg vaccine trial conducted in Uganda sanctioned by the government, occurred in February 2025, for the 40 participants, of the Sabin Vaccine Institute’s cAd3-Marburg. Leaving a regulatory and evidence field gap for the emergency deployment of developers, and giving both field evidence and a regulatory path.
- Preparedness Funded By The Public: Funding in excess of $2 million to support Uganda’s Marburg outbreak, which included vaccine research and surveillance, was mobilized by the WHO and its partners in 2025. This funding mechanism should provide for advance purchasing and decrease the funding gap for outbreak response and vaccine programs.
- Manufacturing Partnerships for The Region: In March 2025, Africa CDC said it was partnering with multiple manufacturers in Africa to build vaccine manufacturing capacity to meet 60 percent of the continent’s needs by 2040. Building regional capacity will shorten the lead time on demand for vaccine platforms.
- Procurement Driven By Stockpiling: In January 2025, over 100 million doses of Ebola vaccine had been deployed internationally through the response mechanisms. This demonstrates how an inventory stockpile can fill irregular demand for outbreaks and create a recurring government procurement contract.
- Platform Technology Competition: In May 2025, CEPI continued efforts to speed up its rapid response vaccine programs to develop candidate vaccines in 100 days following the identification of a pathogen. Rapidly developing platforms will put time pressure on suppliers of inactivated vaccines to refine their formulation, shelf-life, and speed of production.
Strategic Growth Opportunities in the Internal Hemorrhagic Fever Inactivated Vaccine Market
The market for internal hemorrhagic fever inactivated vaccines is starting to gain traction as governments enhance outbreak preparedness, biomanufacturers expand capacity, and regulators look for platform technologies for pathogens with no licensed vaccines. Over the 2024-2026 window, procurement will transition towards preparedness contracts from emergency purchases. Lucintel sees opportunities beyond the public sector’s traditional tenders.- Wider Pathogen Applications: Inactivated technologies for Lassa, Crimean-Congo, and Marburg fever could cover a significant unmet need. In January 2025, the WHO’s R&D Blueprint for 2025 prioritized 9 additional pathogens, further justifying public funding for the pipeline. Over the next 3-5 years, governments will prioritize public funding for technologies adaptable to diseases currently controlled by isolation and contact tracing.
- Defense and Biodefense Procurement: National security agencies can create a market for stockpiled vaccines to protect against intentional or high consequence exposure. In February 2025, the U.S. DoD requested $1.8B for biological defense. Longer procurement contracts will improve revenue predictability, and investment in specialized manufacturing capacity will be justified.
- Premium Thermostable Products: Formulations that require less thermal stability will meet the need in unserved markets and lower cost of deployment. Logistics for reliable thermal stability are still gaps in routine immunization that UNICEF reported in May 2025 for more than 100 countries. Over the next 3-5 years thermostability will be an advantage for products in the humanitarian and frontier markets.
- Regional Manufacturing Partnerships: Manufacturing partnerships can help Africa and the Middle East gain value through fill-and-finish, technology transfer, and licensed production. According to the African CDC in February 2025, almost no vaccines used on the African continent were manufactured by African countries. Collaborative efforts to increase domestic capacity can help develop sustainable partnerships and improve the time required for emergency deliveries.
- Surveillance-related Services: Manufacturers can offer serology, pharmacovigilance, and analytics for outbreak readiness as a part of a contract for vaccines. In March 2025, the WHO reported 2,164 cases of suspected viral hemorrhagic fever in Uganda. These services can help transform episodic vaccine sales into prepaid vaccine sales with annual monitoring as a part of a preparedness contract.
Internal Hemorrhagic Fever Inactivated Vaccine Market Drivers and Challenges
Internal hemorrhagic fever inactivated vaccine market growth is occasioned by the emerging trends in the infectious diseases landscape and improvements in vaccine technology and manufacture, supported by public spending. Growth is also supported by investments in preparedness and improvements in disease surveillance. The vaccine market continues to be challenged by high costs, clinical complexity, and low incentives. These forces along with potential synergies affect the market outlook. According to Lucintel, these forces will govern the dynamics of the market going forward.The factors responsible for driving this market include:
- Increasing Outbreak Preparedness: There is an increased need for capability and preparedness to respond to outbreaks. The World Health Organization (WHO) continued prioritizing different pathogenic threats through its Research and Development Blueprint in January 2025. The next phase of the preparatory efforts over the next three to five years is likely to be the formation of national emergency reserves, complemented by regional response frameworks and enhanced outbreak surveillance. This driver, especially, will be critical in the regions that experience repeated outbreaks of Hemorrhagic fevers. However, user demand may be unpredictable, because procurement of emergency vaccines tends to follow outbreaks, rather than occur as a continuation of regular, annual procurement programs.
- Advanced Technologies: The enhancement of inactivated-virus technologies will lead to a more consistent and safer vaccine. WHO picked platform-based vaccine development as a quicker means to respond to emerging pathogens in June 2025. It is expected that in the next three to five years, these developments will lessen the doubts and increase the flexibility of the potential vaccines to fight hemorrhagic-fever viruses. To a greater extent, higher characterization of antigens and production controls would be of great importance during the vaccine regulatory process. Technology will not edify the existing challenges in the vaccination process. Rather, it will improve flexibility and acceptance of the vaccines by the public-sector procurement systems.
- Regulatory Frameworks and Public Health: Regulatory authorities have taken to employing emergency preparedness measures in combination with rapid vaccine assessment. In May 2025, the EU enabled the improved health security architecture and further strengthened the pandemic preparedness framework. Over the next three to five years, focus on non-traditional approaches to effectiveness with a clearer definition and acceptance of animal models and emergency usage will improve the confidence of potential investors. There will, however, be a greater demand for robust safety data since inactivated vaccines must overcome a challenging protective barrier without causing unacceptable adverse side effects.
- Sustainability and Local Manufacturing: Achieving regional vaccine production decreases dependence on distant suppliers, improves emergency access and health security, and is currently being prioritized by many countries. The African Union is focusing on producing 60% of routine vaccines in Africa by 2040. Targeted investments in both public and private manufacturing along with fill-finish and technology transfer agreements in the next few years may create market opportunities. With local manufacturing, vaccine delivery may be faster and can cultivate the need for local equipment, services, and systems. Successful local manufacturing will depend on a workforce with enough capability, available financing, and confirmed market demand.
- Product Innovation and Cost Advantages: There are many opportunities to create better adjuvants, thermostable vaccines, create similar less complex vaccines, and develop vaccines that require fewer doses. All of these are being researched to lower the cost of vaccine distribution and to make vaccines easier for the end user to administer. In September 2025, thermostability of vaccines to be used in remote outbreaks was still a top priority for vaccine developers. Research continues to create vaccines that may meet the challenge of remote outreach in the 3-5 year time frame. This may also decrease distribution waste and increase the end vaccine campaign coverage.
The challenges facing this market include:
- Limited Clinical and Epidemiological Evidence: The sporadic and geographically concentrated nature of many hemorrhagic-fever outbreaks makes building traditional evidence of efficacy difficult, therefore limiting available evidence. In March 2025, WHO continued to identify evidence generation for neglected and emerging pathogens as a central research priority. Developers can expect to face delays the result of small trial populations, rapidly changing outbreak situations, and/or the use of surrogate endpoints or animal models in the next 3 to 5 years. These situations will increase the cost of funding and lead to more difficult decisions from regulatory agencies. With little advancement in surveillance systems and with no standardization of trials, most promising candidates will remain stuck in the research phase.
- Manufacturing and Supply-Chain Constraints: Inactivated vaccines require many resources including a robust biosafety system, a specialized facility, stable inputs, qualified personnel, and rigorous quality assurance. In April 2025, global health organizations remained concerned with the disruption of the vaccine supply caused by shortages of critical biomanufacturing materials. In the next 3 to 5 years, predicted challenges will include insufficient capacity, weaknesses in the cold chain, and heavily import-reliant supplies. Smaller manufacturers may also be unable to meet international standards and will struggle to meet demand for supplies. These challenges will lead to higher costs, longer delivery times, and less capacity to meet changing demand.
- Uncertain Commercial Returns and Affordability: Hemorrhagic fever vaccines have issues of predictability and serve markets that are predominately public, which may discourage private investment. During the July 2025 discussions on global health financing, advance commitments and blended financing were emphasized for vaccines for neglected diseases. In the coming 3 to 5 years, insufficient procurement assurances may lead to reductions in late-stage clinical trials and manufacturing capacity. High development costs may result in prices that are unaffordable LMICs. To create and sustain demand, lower income countries will require support in the form of donor funding, pooled procurement, and procurement at lower prices with longer government purchasing contracts.
List of Internal Hemorrhagic Fever Inactivated Vaccine Market Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies internal hemorrhagic fever inactivated vaccine market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.Some of the internal hemorrhagic fever inactivated vaccine market companies profiled in this report include:
- Merck & Co.
- IAVI
- Sanofi Pasteur
- Green Cross
- Luoyi (Wuxi) Biopharmaceutical
- Changchun Institute of Biological Products
- Aimei Weixin Biopharmaceutical
Internal Hemorrhagic Fever Inactivated Vaccine Market by Segment
The study includes a forecast for the global internal hemorrhagic fever inactivated vaccine market by type, application, and region.Type [Value ($B) from 2019 to 2035]:
- Yellow Fever Vaccine
- Dengue Vaccine
- Ebola Vaccine
Application [Value ($B) from 2019 to 2035]:
- Hospital
- Clinic
Region [Value ($B) from 2019 to 2035]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Internal Hemorrhagic Fever Inactivated Vaccine Market
The global internal hemorrhagic fever inactivated vaccine market is primarily dominated by East Asia, with the West utilizing fewer vaccines. From 2025 to 2027, government support, preparation for outbreaks, and platform investments will be more prominent than major market launches. According to Lucintel’s recently published data, the ability to manufacture vaccines at the country level will matter most.- United States: Countermeasures for hemorrhagic fevers continue to be a focus of Federal preparedness through BARDA and the National Institutes of Health and were emphasized in 2025 with the absence of any licensed inactivated hemorrhagic fever vaccines. Zero domestic cases of Ebola reported in the U.S. in 2024 allows stockpiles and investigational products to remain a focus. This policy focus will encourage procurement of technologies over private sector vaccination.
- China: As the primary commercial provider of inactivated HFRS vaccines, demand is sustained with public health programs and domestic production. The National Health Commission reported 1,155 cases of HFRS in 2023. 2025 did not bring any confirmed expansions to capacity. The combination of disease surveillance and local vaccinations will sustain China’s manufacturing and consumption through 2030.
- Germany: In contrast to approved inactivated hemorrhagic-fever products, focus is more dedicated to biotechnology and contract manufacturing, as well as regulatory support. The Paul-Ehrlich-Institute reported authorization for 3,148 clinical trials in 2024 showing the development focus. Continued EU Preparedness funding and GMP focus will support partnership and technology transfer for the next three to five years.
- India: India has yet to formally announce a licensed inactivated hemorrhagic fever vaccine or dedicated a 2025 manufacturing capacity increase. The Indian Council of Medical Research (ICMR) has over 100 translational research institutes/centers. Funding a specific program for HFRS or other viral-hemorrhagic-fever research could enable the ICMR to develop outbreak vaccines. Thus, enhanced governmental funding could further facilitate domestic development.
- Japan: Japan reported zero cases of locally acquired Ebola in 2024. A licensed inactivated hemorrhagic fever vaccine for 2025 has not been announced. Japan’s Pharmaceuticals and Medical Devices Agency along with Japanese research institutions and a robust infrastructure for infectious disease preparedness may make Japan a good partnership and regulatory support market, but current demand is predicted to remain low.
Features of the Global Internal Hemorrhagic Fever Inactivated Vaccine Market
- Market Size Estimates: internal hemorrhagic fever inactivated vaccine market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2025 to 2031) by various segments and regions.
- Segmentation Analysis: internal hemorrhagic fever inactivated vaccine market size by type, application, and region in terms of value ($B).
- Regional Analysis: internal hemorrhagic fever inactivated vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the internal hemorrhagic fever inactivated vaccine market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the internal hemorrhagic fever inactivated vaccine market.- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers the following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the internal hemorrhagic fever inactivated vaccine market by type (yellow fever vaccine, dengue vaccine, and ebola vaccine), application (hospital and clinic), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- Merck & Co.
- IAVI
- Sanofi Pasteur
- Green Cross
- Luoyi (Wuxi) Biopharmaceutical
- Changchun Institute of Biological Products
- Aimei Weixin Biopharmaceutical
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

LOADING...

